229. Autoimmune pulmonary alveolar proteinosis Clinical trials / Disease details


Clinical trials : 43 Drugs : 34 - (DrugBank : 8) / Drug target genes : 3 - Drug target pathways : 14

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02702180
(ClinicalTrials.gov)
May 9, 201628/2/2016Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients IMPALAAutoimmune Pulmonary Alveolar ProteinosisDrug: molgramostim;Drug: placeboSavara Inc.NULLCompleted18 Years75 YearsAll139Phase 2/Phase 3United States;Australia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Turkey;United Kingdom;Poland;Romania
2NCT02840708
(ClinicalTrials.gov)
May 201613/7/2016SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic StudySK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic StudyPulmonary Alveolar Proteinosis, AutoimmuneDrug: SargramostimNiigata University Medical & Dental HospitalNULLCompleted20 Years80 YearsAll14Phase 1Japan
3NCT02468908
(ClinicalTrials.gov)
May 20153/6/2015Inhaled Molgramostim (rhGM-CSF) in Healthy Adult SubjectsA Randomized, Double-Blind, Placebo-Controlled, Single-Centre, Single Ascending Dose and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Molgramostim When Administered by Inhalation to Healthy Adult SubjectsPulmonary Alveolar Proteinosis;Bronchiectasis;Cystic Fibrosis;Acute Respiratory Distress SyndromeDrug: Molgramostim;Drug: PlaceboSavara Inc.CelerionCompleted18 Years55 YearsAll42Phase 1United Kingdom
4NCT01983657
(ClinicalTrials.gov)
January 20127/11/2013Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.Study of Subcutaneous Injection of Low-dose Recombinant Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) +/- Whole Lung Lavage(WLL) in Pulmonary Alveolar Proteinosis.Pulmonary Alveolar ProteinosisDrug: rhGM-CSF;Procedure: Whole Lung Lavage(WLL)Shanghai Pulmonary Hospital, Shanghai, ChinaNULLRecruiting17 Years80 YearsBoth40Phase 2China